Introduction
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy characterized by a massive expansion of malignant hematopoietic progenitors and precursors as well as differentiated hematopoietic cells. In addition, in CML, the premature release of progenitors from the bone marrow cavity results in the presence of large numbers of circulating progenitors and extramedullary hematopoiesis. The abnormal accumulation and circulation of hematopoietic progenitors in CML may at least in part result from altered interactions of CML hematopoietic progenitors with the hematopoietic microenvironment. 1, 2 In normal hematopoiesis, the ␤1 integrin family of adhesion receptors, in particular ␣4␤1 and ␣5␤1 receptors, plays an important role in progenitor adhesion and homing to the marrow microenvironment. [3] [4] [5] In addition, signals transduced by ␤1 integrin receptors, like cytokine receptors, regulate normal hematopoietic progenitor Correspondence: R Bhatia, Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91006, USA; Fax: 626 301 8973 Received 8 June 1998; accepted 30 July 1998 proliferation and differentiation. [6] [7] [8] Although malignant CML progenitors express normal levels of ␤1 integrin receptors on the cell surface, they demonstrate deficient ␤1 integrinmediated adhesion to stroma and ␣4␤1 and ␣5␤1 binding regions of fibronectin (FN), indicating abnormal ␤1 integrin function. 9 CML progenitors are also unresponsive to ␤1 integrin-mediated inhibition of proliferation. 10 Thus, abnormalities in integrin function may contribute to both the abnormal circulation and continuous unregulated proliferation of CML hematopoietic progenitors.
The characteristic cytogenetic abnormality in CML is a translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] which leads to the fusion of the c-ABL gene on chromosome 9 with the BCR gene on chromosome 22 and the formation of the BCR/ABL fusion gene. [10] [11] [12] Several in vitro and in vivo studies have demonstrated that the BCR/ABL gene plays a critical role in the pathogenesis of CML. 13, 14 The BCR/ABL gene product p210 BCR/ABL contains several functionally important domains. These include an N-terminal BCR-derived segment and an ABL-derived portion containing non-catalytic Src homology SH2 and SH3 domains, a tyrosine kinase domain and a unique C-terminal region containing nuclear localization, DNA-binding and actin-binding domains. 15 The tyrosine kinase domain appears to be especially critical for the transforming ability of BCR/ABL. 13, 16 Fusion of N-terminal BCR sequences to the ABL tyrosine kinase results in significant enhancement of the tyrosine kinase activity of BCR/ABL 16 and its predominantly cytoplasmic localization. A variety of focal adhesion proteins such as paxillin, tensin and FAK, which are involved in normal integrinmediated signaling are abnormally phosphorylated in BCR/ABL expressing cell lines. [17] [18] [19] Interaction of BCR/ABL SH2 and SH3 domains with the signal transducing proteins crkl and cbl, may lead to its association with, and phosphorylation of, the focal adhesion protein paxillin and the p85 regulatory unit of the phosphoinositide-3 (PI-3) kinase, respectively. [20] [21] [22] [23] Alternatively, BCR/ABL demonstrates enhanced actin binding which may allow its colocalization with and phosphorylation of other cytoskeletal proteins. Such interactions between p210 BCR/ABL and cytoskeletal elements important for ␤1 integrin signaling may underlie abnormal ␤1 integrin function in CML.
We have recently shown that inhibition of BCR/ABL expression in primary malignant CML CD34 +
DR
+ cells with breakpoint-specific AS-ODNs can restore integrin-mediated adhesion and inhibition of proliferation of CML progenitors, indicating a role for p210 BCR-ABL in abnormal CML integrin function. 24 In the present study, we sought to evaluate the role of protein tyrosine phosphorylation by the BCR/ABL tyrosine kinase in abnormal CML integrin function. Protein tyrosine kinase inhibitors can be used to study the role of protein tyrosine kinases in cellular processes and elucidate their signal transduction mechanisms. The tyrphostins are a large family of several hundred PTK inhibitors modeled on the naturally occurring compound erbstatin. 25 Tyrphostins act through specific inhibition of ATP and/or substrate binding to PTKs. Tyrphostins with potent activity against the abl family of PTKs share structural similarity to Lavendustin A whose active pharmacaphore is 2-hydroxy-5-(2,5-dihydroxy-benzyl) aminobenzoic acid, and also contain a 2,5-dihydroxy phenyl ring analogous to erbstatin and the diaryl motif observed in piceatannol. 26 One such agent is Tyrphostin AG957 (AG957), which is 13 times more potent in inhibiting the BCR/ABL kinase compared with c-ABL. 27 Inhibition of BCR/ABL PTK activity by this compound is associated with inhibition of growth of the CML blast crisis-derived cell line K562. 26 In the present study, we evaluated the effect of AG957 on integrin-mediated adhesion and proliferation inhibitory signaling in CML hematopoietic progenitors. Since AG957 could have effects unrelated to its activity against p210 BCR/ABL , related to non-specific inhibition of other PTKs, we also evaluated the effect of Tyrphostin AG555 (AG555), another PTK inhibitor which also inhibits growth of K562 cells but which does not have significant activity against the BCR/ABL kinase. 26 We demonstrate here that AG957, at doses that do not affect progenitor growth in culture, can restore normal integrin-mediated cellular responses in CML progenitors but does not affect integrin function in normal progenitors. These studies suggest an important role for abnormal protein tyrosine phosphorylation in deficient integrin function in CML.
Materials and methods
Eleven patients with CML and seven normal healthy volunteers were evaluated after informed consent was obtained using guidelines approved by the Committee on the Use of Human Subjects at the University of Minnesota and the Institutional Review Board at the City of Hope National Medical Center. Heparinized bone marrow samples were obtained by aspiration from the posterior iliac crest. Bone marrow mononuclear cells (BMMNC) were isolated by Ficoll-Hypaque (Sigma Diagnostics, St Louis, MO, USA) density gradient separation (specific gravity 1.077) for 30 min at 37°C and 400 g.
Selection of CD34
+ progenitor subpopulations CD34 + cell-enriched populations were selected from CML or normal BMMNC using sequential avidin-biotin immunoadsorbtion columns (CellPro, USA, Bothell, WA, USA) or immunomagnetic column separation (Miltenyi Biotech, Auburn, CA, USA). CD34
+ HLA-DR + cells were then selected by FACS sorting as previously described. 28 
Preparation of adhesive substrates
Bone marrow stromal layers were established from normal BMMNC as previously described. 28 75-kDa tryptic fragments of human plasma fibronectin (FN) containing the cell binding sequence RGDS and a recombinant 51-kDa COOH-terminal FN fragment containing the heparin binding and CS1 domains were a kind gift from Dr James B McCarthy, University of Minnesota, Minneapolis, MN, USA. 29 The FN fragments were adsorbed to wells of a 48-well plate as previously described. 4 Control wells were adsorbed with 5 mg/dl bovine serum albumin (BSA) (Ͼ99% pure, fatty acid free; Sigma) alone.
Exposure to tyrphostins

CML and normal CD34
+ DR + cells suspended in defined medium (see below) were exposed to Tyrphostin AG957 or AG555 (obtained as a kind gift from Dr Edward Sausville, Bethesda, MD, USA and from Calbiochem, La Jolla, CA, USA) for 60 min at 37°C in a humidified atmosphere with 5% CO 2 . Cells were washed three times with warm IMDM prior to use in adhesion, proliferation and other assays.
Adhesion assays
Ten thousand CML and normal CD34 + DR + cells were cocultured with irradiated normal stromal layers or with FN-coated plates as previously described. 10, 30 Following coculture, stromal layers were washed three times with warm IMDM and non-adherent cells collected. Adherent cells were harvested using Trypsin EDTA (Sigma). Both adherent and non-adherent fractions were plated in short-term methylcellulose assay for 14-18 days and assessed for the presence of CFU-GM, BFU-E and CFU-MIX colonies as previously described. 31 The percent adherent colony forming cells (CFC) was calculated as: [adherent CFC divided by (adherent CFC + non-adherent CFC)] × 100.
Proliferation assays
The proliferation of CML and normal CFC was evaluated using thymidine suicide assays. To induce proliferation, selected CML and normal CD34 + DR + cells were cultured in defined medium supplemented with low levels of cytokines similar to normal stroma-conditioned long-term bone marrow culture (LTBMC) medium (granulocyte colony-stimulating factor (25 pg/ml), granulocyte-macrophage colony-stimulating factor (10 pg/ml), leukemia inhibitory factor (50 pg/ml), stem cell factor (200 pg/ml), interleukin-6 (1 ng/ml) and macrophage inflammatory protein-1␣ (200 ng/ml)). Ten thousand CML and normal CD34 + DR + cells were cocultured with stroma, FN or anti-␤1 integrin antibodies for 4 h. The proliferation of CFC following culture with or without stroma, FN or anti-␤1 integrin antibodies was evaluated in thymidine suicide assays as previously described. 7, 10 The percentage of CFC in S-phase was calculated as the percentage of CFC killed in the presence of 3 H-thymidine ͕% CFC in S-phase = [(CFC present in absence of 3 H-thymidine − CFC present in presence of 3 Hthymidine) × 100] divided by CFC present in the absence of 3 H-thymidine͖. For stroma, the proliferation of stromaadherent and non-adherent CFC was evaluated separately.
In vitro kinase assays
The effect of Tyrphostins AG555 and AG957 on BCR/ABL kinase activity was evaluated by performing in vitro kinase assays using previously described methods.
26 K562 cells were washed with cold PBS and lysed in buffer containing 50 mm Tris pH 8.0, 150 mm sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 5 mm EDTA and 0.02% sodium azide. Lysis supernatants were precleared for immunoprecipitation with protein A-agarose (Calbiochem, San Diego, CA, USA). BCR/ABL immunoprecipitation was done with protein A-agarose sepharose loaded with Ab-2 antibody directed against BCR (Calbiochem). Immunopreciptates were washed twice with lysis buffer followed by two washes with Tris-HCl, 50 mm, pH 7.0. For each reaction immunoprecipitates corresponding to 5 × 10 6 cells were suspended in 20 l of 20 mm Pipes buffer (20 mm Pipes, 20 mm manganese chloride, pH 7.0). Five microliters of Tyrphostins AG957 or AG555 (at 5× the desired concentration) and 1 l of ␥ 32 P ATP (250 Ci, 6000 Ci/mMol) (Amersham, Arlington Heights, IL, USA) were then added and the reaction mixture incubated at 37°C for 20 min. Immunoprecitates were washed three times with lysis buffer and resolved on a 7% SDS-PAGE gel. The gel was washed with distilled water, dried and autoradiographed overnight. The level of BCR/ABL autophosphorylation in Tyrphostin-treated and control immunoprecipitates was compared.
Western blotting
Western immunoblotting to detect tyrosine phosphorylated proteins was performed using a modification of previously described methods.
32 K562 and BCR/ABL-tranfected M07e cells (MBA-4) 33 (a kind gift from Dr John Dick, Toronto, Canada) were incubated with Tyrphostin AG957 and AG555, as described in the Results, washed with cold PBS and lysed in buffer containing 50 mm Tris pH 8.0, 150 mm sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 5 mm EDTA and 0.02% sodium azide, sodium fluoride, sodium orthovanadate, PMSF, leupeptin and aprotinin. Protein extracts were resolved on 7% or 10% SDS-PAGE gels, transferred to PVDF membranes, blocked for 4 h with 5% non-fat milk in PBS and incubated for 16 h with 1:1000 dilution of anti-phosphotyrosine antibody (4G10) (a kind gift from Dr BJ Druker, Portland, OR, USA). Membranes were washed with PBS with 0.1% Tween and incubated with 1:2500 dilution of goat anti-mouse antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research, West Grove, PA, USA) for 2 h. Following extensive washing, antibody detection was done using a Western blot enhanced chemiluminescence (ECL) system (Amersham). Membranes were stripped using 2% SDS, 7 mm 2-mercaptoethanol, 0.2 m Tris-buffered saline, pH 7.5 at 50°C for 30 min, and were restrained with primary antibodies directed against the following proteins: c-Abl (1:3000) (antibody Ab-3, Oncogene Science, Manhasset, NY, USA), paxillin (1:500), tensin (1:250) (Transduction Laboratories, Lexington, KY, USA), Cbl (1:500), Crkl (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the p85 subunit of PI-3 kinase (1 g/ml) (Upstate Biotechnology, Lake Placid, NY, USA). Secondary goat anti-mouse and goat anti-rabbit HRP-conjugated antibodies (Jackson ImmunoResearch) were used, as appropriate, and antibody detection was done using an ECL system.
Statistical analysis
Results of experimental points obtained from multiple experiments were reported as mean ± s.e.m. Significance levels for differences between different samples was determined using two-tailed Student's t-test.
Results
Effect of Tyrphostin AG957 on growth of CML and normal CFC
The effect of incubation of CD34 + cells with AG957 and AG555 at concentrations ranging from 0.1 to 50 m for 1 h on subsequent growth of CFC was evaluated. A significant dosedependent inhibition of CML CFC growth was seen following preincubation with AG957 but was not seen following preincubation with AG555 ( Figure 1 ). This pattern of inhibition was not specific to CML CFC since a similar pattern of inhibition was seen with normal CFC (Figure 1) . In vitro kinase assays confirmed significant dose-dependent inhibition of BCR/ABL kinase activity by AG957 (Figure 2) . AG555, on the other hand, did not significantly inhibit BCR/ABL PTK activity at the concentrations studied. The highest concentration of AG957 that did not have any effect on CML or normal CFC growth was 0.5 m for 60 min. This concentration was associated with partial but significant inhibition of BCR/ABL kinase activity. Subsequent experiments to evaluate the effect of suppression of BCR/ABL PTK activity by AG957 on ␤1 integrin function in CML progenitors were therefore carried out by using 0.5 m AG957.
Tyrphostin AG957 restores CML CFC adhesion to stroma or fibronectin
Adhesion of CML CFC to stroma and FN was evaluated following incubation of CML CD34
+ cells with AG957 and AG555 at 0.5 m for 60 min. Preincubation with AG957 resulted in significantly increased adhesion of CML CFC to stromal layers (Figure 3) . The control AG555 did not significantly affect CML CFC adhesion to stroma. CML CFC adhesion to the ␣5␤1 integrin binding 75-kDa fragment of FN as well as the ␣4␤1 binding 51-kDa FN fragment was significantly enhanced by AG957 but was not affected by AG555 (Figure 3 ). These observations indicate that AG957, a tyrosine kinase inhibitor with activity against the BCR/ABL kinase, can at least partially overcome defective adhesion of CML CFC to ␣4␤1 and ␣5␤1 integrin binding fragments of FN.
Tyrphostin AG957 restores ␤1 integrin-dependent inhibition of CML CFC proliferation
FACS-selected CML CD34
+ cells were induced to proliferate by culture for 4 days in serum-free defined medium with cytokines. As described in our previous studies, proliferation of untreated CML CFC was not significantly reduced following coculture with stroma or FN fragments. 10 Preincubation with AG957 (0.5 m) for 60 min did not alter proliferation of CML CFC kept in suspension but resulted in significant reduction in proliferation of CML CFC following coculture with stroma ( Figure 4) . Reduced proliferation following contact with stoma was the result of inhibition of proliferation of adherent CFC whereas proliferation of non-adherent CFC was not affected by AG957 preincubation. AG957 preincubation also resulted in significant reduction in CML CFC proliferation following culture in wells coated with the ␣5␤1 integrin binding FN-75-kDa fragment as well as the ␣4␤1 integrin binding 51-kDa FN fragment ( Figure 5 ). Like AG957, AG555 did not affect proliferation of CML CFC in suspension. In contrast to AG957, AG555 did not significantly change CML CFC proliferation following culture with either stroma or FN (Figures 4 and 5) .
In additional experiments, we examined the effect of direct antibody-mediated stimulation of ␤1 integrin receptors on CML CFC proliferation. Stimulation of ␤1 integrin receptors with blocking anti-␤1 integrin mouse monoclonal antibodies does not reduce proliferation of untreated CML CFC ( Figure  6 ). However, AG957 pretreatment resulted in significant inhibition of proliferation of CML CFC following antibodymediated engagement of ␤1 integrin receptors ( Figure 6 ). This effect was not observed following AG555 pretreatment ( Figure  6 ). These observations indicate that AG957 pretreatment can restore ␤1 integrin-mediated inhibition of CML CFC proliferation.
Lack of effect of Tyrphostin AG957 on normal CFC
Incubation of normal CD34
+ cells with AG957 (0.5 mm for 60 min) did not alter the adhesion of normal CFC to FN-75 kDa (Figure 7 ). AG957 did not affect proliferation of normal CFC in suspension nor inhibition of normal CFC proliferation seen following coculture with FN-75 kDa or following integrin receptor engagement with anti-␤1 integrin antibodies ( Figure 7) . These results indicate that the effects of AG957 on CML CFC adhesion and proliferation are not the result of nonspecific effects of tyrosine kinase inhibition on adhesion or proliferation, and support a role for abnormal tyrosine phosphorylation in defective integrin function in CML progenitors. As was observed for CML CFC, preincubation with AG555 did not affect normal CFC adhesion or proliferation, either in suspension or following adhesion to FN-75 kDa and integrin receptor crosslinking with anti-␤1 integrin antibodies ( Figure  7) .
Effect of Tyrphostin AG957 on protein tyrosine phosphorylation of BCR/ABL PTK substrates
The effect of AG957 and AG555 on protein tyrosine phosphorylation in K562 and BCR/ABL transformed M07e (MBA-4) cells was evaluated by Western blot. Cells were incubated for 24 h with and without 25 m AG957 and AG555 and protein tyrosine phosphorylation analyzed by Western blotting with anti-phosphotyrosine antibodies. The higher concentration of AG957 and longer duration of incubation were chosen as K562 and MBA-4 cells are more resistant to the effects of AG957 compared with CML and normal CFC (25 m AG957 for 24 h resulted in 50% and 52% growth suppression of K562 cells and MBA-4 cells respectively, which is similar to growth suppression observed in CD34 + cells with 1-2 m AG957 for 60 min). As shown in Figure 8 , AG957 partially inhibited tyrosine phosphorylation of p210 BCR/ABL , the focal adhesion protein paxillin, the p85 regulatory subunit of the PI-3 kinase and the adapter protein cbl in K562 cells. In MBA-4 cells, AG957 inhibited phosphorylation of these proteins as well as the adapter protein crkl. The focal adhesion protein tensin was not detectable in either of these cell lines by Western blotting. As previously described for BCR/ABL transformed cell lines, paxillin was present mainly in lower molecular weight forms, which were also tyrosine phosphorylated and were dephosphorylated following AG957 treatment. 34 In addition to inhibition of phosphorylation, AG957 also induced the formation of high molecular weight complexes of p210 BCR/ABL , paxillin, p85 and crkl (not shown) with reduction in the amounts of these proteins in the native state. This is consistent with previous reports that AG957 alters the physical state of p210 BCR/ABL and the signaling molecules Shc and Grb-2 in K562 cells, causing formation of high molecular weight complexes containing these proteins with decrease in the amounts of native p210 BCR/ABL , Shc and Grb-2.
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Figure 2
Effect of Tyrphostins AG957 and AG555 on p210BCR/ABL tyrosine kinase activity. BCR/ABL immunoprecipitates were prepared from K562 cells using protein A sepharose beads preloaded with Ab-2 antibody directed against BCR, as described in the text. Immunoprecipitates derived from 5 × 10 6 cells were incubated with ␥ 32 P ATP with or without Tyrphostins AG957 or AG555 being present in the reaction mixture, washed, resolved on a 7% SDS-PAGE gel and autoradiographed (a). The level of BCR/ABL autophosphorylation in Tyrphostin-treated and control immunoprecipitates was compared by densitometry (n = 3) (b).
Figure 3
Tyrphostin AG957 restores CML CFC adhesion to stroma or fibronectin. CML DR + cells (10 000 per condition) were incubated with or without Tyrphostin AG957 and AG555, 0.5 m for 60 min. After three washes, progenitor adhesion to (a) stromal adherent layers (n = 6), (b) BSA (n = 7), (c) FN-75 kDa (n = 6) and (d) FN-51 kDa (n = 3) was evaluated as described in the text. Results shown represent the mean ± s.e.m. for separate experiments. Significance levels *P Ͻ 0.001 and #P Ͻ 0.03 compared with adhesion of untreated controls. the other hand did not significantly alter phosphorylation of BCR/ABL or BCR/ABL substrates.
Discussion
In the present study, we demonstrate that the PTK inhibitor Tyrphostin AG957, which has activity against the BCR/ABL PTK, restores ␤1 integrin-mediated adhesion and microenvironmental growth regulation in CML hematopoietic progenitors but does not affect ␤1 integrin function in normal hematopoietic progenitors. Tyrphostin AG555, another PTK inhibitor which does not have anti-BCR/ABL PTK activity, did not affect integrin function in CML progenitors. Treatment of BCR/ABL containing cells with AG957 was associated with reduced tyrosine phosphorylation of cytoskeletal and signaling proteins that could contribute to abnormal integrin signaling. These observations suggest that BCR/ABL-induced tyrosine phosphorylation plays an important role in abnormal ␤1 integrin function in CML progenitors.
CML progenitors demonstrate deficient ␣4␤1 and ␣5␤1 integrin-mediated adhesion to stroma and fibronectin 9 and are unresponsive to ␤1 integrin-mediated inhibition of proliferation following contact with stroma and fibronectin and antibody-mediated receptor engagement. 10 In previous studies we have shown that AS-ODN-mediated inhibition of BCR/ABL expression restores ␤1 integrin-mediated adhesion and proliferation inhibition in CML progenitors. 24 In other studies, BCR/ABL expression has been reported to enhance the shortterm adhesion of hematopoietic cell lines to FN 36 and alter the mobility and shape of cells plated on FN substrates. 34 These studies suggest that abnormal integrin-mediated cellular responses in CML are related to the presence of the BCR/ABL gene. We now demonstrate that low concentrations of the BCR/ABL PTK inhibitor AG957, associated with partial inhibition of BCR/ABL kinase activity, significantly enhance adhesion of CML progenitors to stroma and fibronectin, similar to what was observed following AS-ODN-mediated inhibition of BCR/ABL expression, in previous studies. 24 In addition, AG957 restored inhibition of CML progenitor proliferation following coculture with stroma, fibronectin and anti-␤1 integrin antibodies but did not directly affect proliferation of progenitors in suspension. Restoration of receptor
Figure 4
Tyrphostin AG957 restores inhibition of CML CFC proliferation following coculture with stroma. CML DR + cells (10 000 per point) were cultured in defined medium for 96 h to induce proliferation and then incubated with or without Tyrphostin AG957 and AG555 0.5 m for 60 min. After three washes, cells were either kept in suspension or were cocultured with stroma for 4 h. After 4 h, stromal layers were washed and non-adherent and adherent cells harvested. The proliferation status of cells in (a) suspension, (b) cocultured with stroma (all cells, adherent + non-adherent) (c) stroma adherent cells and (d) stroma non-adherent cells, was evaluated using thymidine suicide assays as described in the text. Results represent the mean ± s.e.m. for six separate experiments. Significance levels *P Ͻ 0.002 compared with proliferation of untreated controls.
Figure 5
Tyrphostin AG957 restores inhibition of CML CFC proliferation following coculture with fibronectin. CML DR + cells (10 000 per point), following culture in defined medium for 96 h to induce proliferation, were incubated with or without Tyrphostin AG957 and AG555 0.5 m for 60 min. After three washes, cells were either kept in (a) suspension (n = 7) or were cocultured with (b) FN-75 kDa (n = 6) or (c) FN-51 kDa (n = 3) for 4 h. Progenitor proliferation was subsequently evaluated using thymidine suicide assays as described in the text. Results represent the mean ± s.e.m. for separate experiments. Significance levels *P Ͻ 0.01 and #P Ͻ 0.02 compared with proliferation of untreated controls.
function was observed for both ␣4␤1 and ␣5␤1 integrins. The results of the present study therefore support the proposed role for the BCR/ABL gene in abnormal integrin function in CML and further suggest an important role for BCR/ABL-induced abnormal tyrosine phosphorylation in abnormal integrinmediated cellular responses in CML progenitors.
AG957 inhibited BCR/ABL kinase activity in a dose-dependent manner, with significant inhibition seen after exposure to concentrations as low as 0.5 m for 1 h and complete inhibition at 25 m. AG957 also resulted in significant dosedependent inhibition of CML CFC growth at concentrations in excess of 1 m. AG555, another PTK inhibitor which has potent growth inhibitory effects on K562 cells but which does not inhibit the BCR/ABL PTK, did not suppress CML CFC growth even at concentrations as high as 50 m. However, normal CFC growth was similarly inhibited by AG957, indicating that inhibition of CML CFC growth by AG957 cannot be attributed to inhibition of BCR/ABL PTK activity alone, and that it likely occurs through non-specific inhibition of other PTKs in addition to Abl family kinases. We therefore evaluated the effect of Tyrphostin AG957 on ␤1 integrin function in CML progenitors following exposure of cells to 0.5 m AG957 for 1 h, which is associated with partial but significant inhibition of BCR/ABL kinase activity but without a direct effect on CML or normal CFC growth. Our results suggest that restoration of integrin-mediated adhesion and proliferation inhibition in Tyrphostin AG957 restores inhibition of CML CFC proliferation following antibody-mediated ␤1 integrin receptor stimulation. CML DR + cells (10 000 per point) which had been cultured in defined medium for 96 h to induce proliferation were incubated with or without Tyrphostin AG957 and AG555 0.5 m for 60 min. After three washes, cells were either incubated with (a) control mouse antibodies or (b) anti-␤1 integrin antibodies for 30 min followed by incubation with goat anti-mouse antibodies for 4 h, as described in the text. Progenitor proliferation was subsequently evaluated using thymidine suicide assays. Results represent the mean ± s.e.m. for seven separate experiments. Significance levels *P Ͻ 0.001 compared with proliferation of untreated controls.
CML progenitors by AG957 may be related to its effects on BCR/ABL since (1) AG957 did not affect integrin function in normal progenitors and (2) AG555, which does not inhibit the BCR/ABL PTK, did not significantly affect integrin function in CML or normal progenitors. Enhanced integrin-mediated adhesion of CML CFC following AG957 exposure could not result from selective outgrowth of coexisting normal progenitors within the CML CD34 +
DR
+ population since the total number of CFC, adherent plus non-adherent, did not change following AG957 exposure for 60 min, and because AG957 did not selectively suppress CML compared with normal CFC at the concentration used.
Normal integrin signaling requires interaction of the ␤1 integrin receptor cytoplasmic tail with cytoskeletal elements such as ␣-actinin, talin, vinculin tensin and paxillin and tyrosine kinases such as FAK and RAFTK, in multi-protein focal adhesion complexes. [37] [38] [39] Integrin signaling is associated with cytoskeletal rearrangement, changes in protein tyrosine phosphorylation and activation of downstream signaling cascades including the PI-3 kinase pathway, which may also modulate integrin function. [39] [40] [41] Observations made in BCR/ABL expressing cell lines suggest that p210 BCR/ABL can associate with and/or phosphorylate several cytoskeletal and cytoskeleton-associated signaling proteins important for normal integrin function. For example, the focal adhesion proteins paxillin, vinculin, talin and tensin as well as FAK and the PI-3 kinase are abnormally phosphorylated in BCR/ABL expressing cells. 17, 23 The adapter proteins crkl and cbl, which associate with and are phosphorylated by p210 BCR-ABL , link p210
BCR-ABL with paxillin and the PI-3 kinase p85 subunit, respectively. 21, 22 In addition to enhanced tyrosine kinase activity, p210 BCR/ABL demonstrates enhanced actin binding compared with p140 c-ABL . [42] [43] [44] [45] The resultant cytoskeletal alterations could perturb the normal p140 c-ABL functions and contribute to abnormal integrin function in CML. 42, 44 Alternatively, cytoskeletal binding may allow colocalization of BCR/ABL with focal adhesion proteins which are substrates for BCR/ABLinduced tyrosine phosphorylation.
Our observation that partial inhibition of p210 BCR/ABL PTK activity with AG957 is associated with restoration of both integrin-mediated adhesion and integrin-mediated proliferation inhibition in CML primary progenitors supports the hypothesis that abnormal phosphorylation of integrin-related proteins plays an important role in abnormal integrin function in CML. AG957 treatment resulted in reduced tyrosine phosphorylation of several signaling proteins potentially involved in integrin function including the cytoskeletal protein paxillin, the p85 subunit of the PI-3 kinase, cbl and crkl was reduced in BCR/ABL-positive cell lines. Treatment with AG957 also induced the formation of high molecular weight complexes of p210 BCR/ABL , paxillin, p85 and crkl, leading to a reduction in the amounts of these proteins in the native state. This is consistent with recent studies indicating that AG957 can alter the physical state of p210 BCR/ABL and induce the formation of high molecular weight (Ͼ210 kDa) complexes of p210 BCR/ABL with Shc and Grb-2. 35 The effect of AG957 on the physical state of p210 BCR/ABL and its downstream signaling molecules may contribute to its ability to counteract BCR/ABL-induced defects in integrin function, since is possible that the binding of p210 BCR/ABL and signaling proteins into complexes may make them unavailable for their usual signal transduction functions, thereby leading to inhibition of signaling pathways involving p210 BCR/ABL and these proteins. The observation that concentrations of AG957 associated with complete inhibition of BCR/ABL activity are toxic to both normal as well as malignant hematopoietic progenitor cells indicates that brief exposure to AG957 may be of limited use for purging malignant progenitors from CML marrow. However, since altered microenvironmental regulation could play an important role in the continuous proliferation and growth advantage of malignant hematopoietic progenitors in CML, restoration of normal integrin-mediated microenvironmental Tyrphostins AG957 and AG555 do not alter normal CFC adhesion or proliferation. Ten thousand normal DR + cells were incubated with or without Tyrphostin AG957 and AG555, as described in the text. After washing, cells were either kept in suspension, cocultured with FN-75 kDa coated wells or incubated with anti-␤1 integrin antibodies or control mouse antibodies for 30 min followed by incubation with goat anti-mouse antibodies for 4 h after which their adhesion and proliferation were evaluated. Results represent the mean ± s.e.m. for three separate experiments.
regulation by lower concentrations of AG957 may retard the growth of malignant cells. This effect would be similar to that of another agent, interferon-␣, that has been used successfully for the treatment of CML. We have previously demonstrated that a potential mechanism of action of interferon-␣ in CML may be the restoration of normal integrin-mediated adhesion and growth inhibitory signaling, with reduction in the growth advantage of CML progenitors over normal progenitors. 10, 30, 46 It may be speculated that chronic, systemic administration of a compound such as AG957 could result in a similar reduction in growth advantage of CML progenitors allowing regrowth of normal hematopoietic cells. To further investigate this possibility, studies investigating the effect of AG957 on the growth of CML and normal progenitors in long-term bone marrow cultures are underway. The recently described agent CGP 57148, which potently and specifically inhibits the BCR/ABL PTK, 47 may be even more effective in this regard.
In conclusion, we demonstrate that the PTK inhibitor AG957, with activity against the BCR/ABL tyrosine kinase, restores normal ␤1 integrin-mediated adhesion and proliferation inhibition in CML progenitors but does not affect integrin function in normal progenitors. Our studies suggest a role for BCR/ABL-induced tyrosine phosphorylation in altered integrin function in CML progenitors, shed some light on the molecular mechanisms underlying p210 BCR-ABL -induced disruption of integrin function in CML progenitors and may have important therapeutic implications.
Figure 8
Effect of Tyrphostin AG957 on protein tyrosine phosphorylation in BCR/ABL transformed cells. K562 (a) and BCR/ABL transformed M07e cells (MBA-4) (b) were incubated for 24 h with and without 25 mm Tyrphostins AG957 and AG555. Following protein extraction, SDS-PAGE and transfer to PVDF membranes, protein tyrosine phosphorylation was analyzed by immunoblotting with a monoclonal anti-phosphotyrosine antibody (4G10) (Anti-PY). Subsequently, the membranes were stripped and immunoblotted with anti-c-Abl, anti-cbl, anti-p85 PI-3 kinase, anti-paxillin, anti-tensin and anti-crkl antibodies and compared with the corresponding bands in the phosphotyrosine immunoblot.
